MCID: THY023
MIFTS: 64

Thymoma

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymoma

MalaCards integrated aliases for Thymoma:

Name: Thymoma 12 75 55 6 44 15 17 72
Thymus Neoplasms 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3275
MeSH 44 D013945
NCIt 50 C3411
UMLS 72 C0040100 C3714644

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to thymoma, familial and epithelial malignant thymoma. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and Class I MHC mediated antigen processing and presentation. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include thymus, t cells and lung, and related phenotypes are neoplasm of the thymus and abnormality of the mediastinum

Wikipedia : 75 A thymoma is a tumor originating from the epithelial cells of the thymus that may be benign or... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 700)
# Related Disease Score Top Affiliating Genes
1 thymoma, familial 35.2 KIT HRAS
2 epithelial malignant thymoma 34.3 LCK CD5
3 spindle cell thymoma 34.3 LCK CD5
4 dendritic cell thymoma 34.3 TTN LCK CD5
5 cortical thymoma 34.0 TTN CD2
6 mixed type thymoma 33.9 KIT CD5
7 myasthenia gravis 33.5 TTN RYR1 IL2 AIRE
8 thymus cancer 33.4 NKX2-1 KIT DPYSL5 DNTT CD5
9 thymic epithelial tumor 33.3 KIT CD5
10 lymphoblastic lymphoma 30.7 PTPRC DNTT CD5
11 small cell carcinoma 30.7 PTPRC NKX2-1 KIT
12 mast cell neoplasm 30.5 KIT IL2 CD2
13 extracutaneous mastocytoma 30.5 PTPRC KIT CD2
14 myeloma, multiple 30.3 PTPRC KIT IL2 HRAS AKT1
15 t cell deficiency 30.1 PTPRC IL2 CD2
16 lymphoma, non-hodgkin, familial 30.1 PTPRC IL2 DNTT CD5
17 follicular dendritic cell sarcoma 30.0 PPL KIT EVPL
18 leukemia, chronic myeloid 29.7 KIT HRAS EVPL DNTT
19 hematologic cancer 29.1 PTPRC KIT IL2 HRAS DNTT CD5
20 leukemia, acute myeloid 29.1 PTPRC KIT IL2 HRAS DNTT CD2
21 immunodeficiency with thymoma 12.6
22 predominantly cortical thymoma 12.4
23 invasive malignant thymoma 12.4
24 type c thymoma 12.3
25 encapsulated thymoma 12.3
26 thymoma type ab 12.3
27 combined thymoma 12.3
28 thymoma type a 12.3
29 thymoma type b 12.3
30 good syndrome 12.2
31 malignant type ab thymoma 12.2
32 noninvasive malignant thymoma 12.2
33 malignant type a thymoma 12.2
34 thymic carcinoma 12.2
35 thymoma, childhood 12.1
36 acquired pure red cell aplasia 11.7
37 pure red-cell aplasia 11.6
38 morvan's fibrillary chorea 11.5
39 limbic encephalitis with lgi1 antibodies 11.2
40 red cell aplasia 10.8
41 maxillary sinus adenoid cystic carcinoma 10.7 KIT IL2
42 autoimmune disease 10.7
43 chromosome 14q11-q22 deletion syndrome 10.7 NKX2-1 HRAS
44 agammaglobulinemia 10.7
45 lung adenoid cystic carcinoma 10.6 NKX2-1 KIT HRAS
46 myopathy, centronuclear, 2 10.6 TTN RYR1
47 respiratory system cancer 10.6 NKX2-1 HRAS AKT1
48 intestinal disease 10.5 IL2 HRAS AKT1
49 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.5
50 hemangioma of lung 10.5 NKX2-1 AKT1

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

32 (show all 29)
# Description HPO Frequency HPO Source Accession
1 neoplasm of the thymus 32 hallmark (90%) HP:0100521
2 abnormality of the mediastinum 32 hallmark (90%) HP:0045026
3 ptosis 32 frequent (33%) HP:0000508
4 diplopia 32 frequent (33%) HP:0000651
5 dysphagia 32 frequent (33%) HP:0002015
6 fatigue 32 frequent (33%) HP:0012378
7 dyspnea 32 frequent (33%) HP:0002094
8 cough 32 frequent (33%) HP:0012735
9 chest pain 32 frequent (33%) HP:0100749
10 lymphadenopathy 32 frequent (33%) HP:0002716
11 fatigable weakness 32 frequent (33%) HP:0003473
12 interstitial pulmonary abnormality 32 frequent (33%) HP:0006530
13 arthritis 32 occasional (7.5%) HP:0001369
14 pancytopenia 32 occasional (7.5%) HP:0001876
15 hemolytic anemia 32 occasional (7.5%) HP:0001878
16 skin rash 32 occasional (7.5%) HP:0000988
17 limitation of joint mobility 32 occasional (7.5%) HP:0001376
18 xerostomia 32 occasional (7.5%) HP:0000217
19 pericarditis 32 occasional (7.5%) HP:0001701
20 myositis 32 occasional (7.5%) HP:0100614
21 abnormality of the pleura 32 occasional (7.5%) HP:0002103
22 alopecia 32 occasional (7.5%) HP:0001596
23 thyroiditis 32 occasional (7.5%) HP:0100646
24 decreased antibody level in blood 32 occasional (7.5%) HP:0004313
25 nephrotic syndrome 32 occasional (7.5%) HP:0000100
26 keratoconjunctivitis sicca 32 occasional (7.5%) HP:0001097
27 myocarditis 32 occasional (7.5%) HP:0012819
28 b lymphocytopenia 32 occasional (7.5%) HP:0010976
29 abnormality of the peritoneum 32 occasional (7.5%) HP:0002585

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.7 HRAS
2 Decreased viability GR00221-A-1 10.7 AKT1 AKT3 HRAS LCK AKT2 KIT
3 Decreased viability GR00221-A-2 10.7 AKT1 AKT3 HRAS LCK TTN
4 Decreased viability GR00221-A-3 10.7 AKT1 AKT3 HRAS LCK AKT2
5 Decreased viability GR00221-A-4 10.7 AKT1 AKT3 TTN AKT2
6 Decreased viability GR00301-A 10.7 AKT3 LCK AKT2 KIT
7 Decreased viability GR00342-S-1 10.7 LCK TTN
8 Decreased viability GR00342-S-3 10.7 LCK TTN AKT2
9 Decreased viability GR00402-S-2 10.7 AKT1 AKT3 HRAS LCK TTN AKT2
10 Decreased substrate adherent cell growth GR00193-A-1 9.9 AKT2 KIT
11 Decreased substrate adherent cell growth GR00193-A-2 9.9 AKT2 AKT3 KIT LCK
12 Decreased substrate adherent cell growth GR00193-A-3 9.9 AKT2 AKT3 LCK
13 Decreased substrate adherent cell growth GR00193-A-4 9.9 KIT LCK
14 Decreased cell migration GR00055-A-1 9.65 AKT1 AKT2 AKT3 HRAS LCK
15 Increased cell viability after pRB stimulation GR00230-A-1 9.02 AKT1 AKT2 AKT3 KIT LCK

MGI Mouse Phenotypes related to Thymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 AIRE AKT1 AKT2 AKT3 DNTT HRAS
2 endocrine/exocrine gland MP:0005379 10.16 AIRE AKT1 AKT2 AKT3 HRAS IL2
3 hematopoietic system MP:0005397 10.13 AIRE AKT1 AKT2 AKT3 CD5 DNTT
4 immune system MP:0005387 10.11 AIRE AKT1 AKT2 AKT3 CD5 DNTT
5 digestive/alimentary MP:0005381 10.02 AIRE HRAS IL2 KIT NKX2-1 PTPRC
6 nervous system MP:0003631 10 AIRE AKT1 AKT2 AKT3 CD5 DPYSL5
7 neoplasm MP:0002006 9.97 AIRE AKT1 AKT2 AKT3 HRAS IL2
8 normal MP:0002873 9.8 AIRE AKT1 AKT2 AKT3 CD2 CD5
9 no phenotypic analysis MP:0003012 9.76 AIRE AKT2 CD5 HRAS IL2 KIT
10 respiratory system MP:0005388 9.32 AIRE AKT1 AKT2 HRAS IL2 KIT

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
4
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7 Antifungal Agents Phase 4
8 Anti-Infective Agents Phase 4
9 Calcineurin Inhibitors Phase 4
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
12
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
13
Bevacizumab Approved, Investigational Phase 3 216974-75-3
14
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
15 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
16 Cola Phase 3
17 Analgesics Phase 3
18 Liver Extracts Phase 3
19 Central Nervous System Depressants Phase 3
20 Narcotics Phase 3
21 Adjuvants, Anesthesia Phase 3
22 Anesthetics Phase 3
23 Anesthetics, General Phase 3
24 Analgesics, Opioid Phase 3
25 Anesthetics, Intravenous Phase 3
26 Antineoplastic Agents, Phytogenic Phase 3
27 Tubulin Modulators Phase 3
28 Albumin-Bound Paclitaxel Phase 3
29 Antimitotic Agents Phase 3
30 Antineoplastic Agents, Immunological Phase 3
31 Immunologic Factors Phase 3
32 Angiogenesis Inhibitors Phase 3
33 Angiogenesis Modulating Agents Phase 3
34 Antibodies Phase 3
35 Antibodies, Monoclonal Phase 3
36 Immunoglobulins Phase 3
37
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
38
Pasireotide Approved Phase 2 396091-73-9 9941444
39
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
40
Melphalan Approved Phase 2 148-82-3 460612 4053
41
Busulfan Approved, Investigational Phase 2 55-98-1 2478
42
Turmeric Approved, Experimental, Investigational Phase 2
43
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
44
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
45
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
46
Sodium citrate Approved, Investigational Phase 2 68-04-2
47
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
48
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
49
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
3 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
4 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
5 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
6 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
7 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
8 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
9 Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS:A Randomized Controlled Trial Recruiting NCT03521986 Phase 3
10 A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer Terminated NCT00520975 Phase 3 Carboplatin;Paclitaxel
11 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Unknown status NCT02607631 Phase 2 Pembrolizumab
12 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Unknown status NCT01802320 Phase 2 Akt Inhibitor MK2206
13 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
14 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
15 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
16 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
17 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
18 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
19 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
20 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
21 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
22 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
23 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
24 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
25 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
26 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
27 Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP) Completed NCT00641147 Phase 2 Curcumin
28 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
29 A Phase II Study of MK-2206 in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed NCT01604772 Phase 2 Akt Inhibitor MK2206
30 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
31 Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation Completed NCT01277757 Phase 2 Akt Inhibitor MK2206
32 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
33 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
34 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum Completed NCT02315430 Phase 2 Cabozantinib S-malate
35 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
36 Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
37 A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma Completed NCT00729586 Phase 2 Megestrol Acetate;Tamoxifen Citrate;Temsirolimus
38 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
39 Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Completed NCT01369849 Phase 1, Phase 2 Akt Inhibitor MK2206;Bendamustine Hydrochloride
40 A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer Completed NCT00126503 Phase 1, Phase 2 Sorafenib Tosylate
41 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
42 A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
43 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
44 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
45 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Recruiting NCT03466827 Phase 2 Selinexor
46 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
47 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
48 Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
49 A Phase II Study of TAS-117 in Advanced Solid Tumors With PI3K/AKT Gene Aberration (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial) Recruiting NCT03017521 Phase 2 TAS-117
50 A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies Recruiting NCT02629419 Phase 2 Amphotericin B

Search NIH Clinical Center for Thymoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Carboplatin
Ifosfamide

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

MalaCards organs/tissues related to Thymoma:

41
Thymus, T Cells, Lung, B Cells, Thyroid, Breast, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

19
Thymus

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 7747)
# Title Authors PMID Year
1
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. 9 38
19876913 2010
2
Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. 9 38
19747927 2010
3
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 9 38
19693092 2009
4
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. 9 38
18635704 2009
5
AKT1 Gene Polymorphisms and Obstetric Complications in the Patients with Schizophrenia. 9 38
20046382 2009
6
Spiradenoma reminiscent of thymoma: report of a case and review of the literature. 9 38
18647207 2009
7
Early loss of mammalian target of rapamycin complex 1 (mTORC1) signalling and reduction in cell size during dominant-negative suppression of hepatic nuclear factor 1-alpha (HNF1A) function in INS-1 insulinoma cells. 9 38
18949455 2009
8
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 9 38
18728167 2008
9
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells. 9 38
18509162 2008
10
Infrequent and low AIRE expression in thymoma: difference in AIRE expression among WHO subtypes does not correlate with association of MG. 9 38
18568643 2008
11
CRMP5 antibodies in patients with small-cell lung cancer or thymoma. 9 38
17657489 2008
12
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. 9 38
18567864 2008
13
Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? 9 38
17928069 2007
14
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. 9 38
17590173 2007
15
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 9 38
17611497 2007
16
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. 9 38
17539937 2007
17
Is excitation-contraction coupling impaired in myasthenia gravis? 9 38
17307394 2007
18
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). 9 38
17334980 2007
19
Expression of p63 in thymomas and normal thymus. 9 38
17276940 2007
20
AKT1 and neurocognition in schizophrenia. 9 38
17464696 2007
21
[Thymus CT scan and thymoma associated antibodies in myasthenia gravis with thymoma]. 9 38
16995304 2006
22
Exogenous nitric oxide stimulates cell proliferation via activation of a mitogen-activated protein kinase pathway in ovine fetoplacental artery endothelial cells. 9 38
16251502 2006
23
[Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors]. 9 38
16608644 2006
24
Titin and ryanodine receptor antibodies in myasthenia gravis. 9 38
16637922 2006
25
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. 9 38
16125946 2005
26
Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. 9 38
16120143 2005
27
Analysis of cell cycle regulator proteins in encapsulated thymomas. 9 38
16033820 2005
28
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. 9 38
15760917 2005
29
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]. 9 38
15634634 2004
30
Association of AKT1 with schizophrenia confirmed in a Japanese population. 9 38
15522255 2004
31
The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. 9 38
15316806 2004
32
Expression of cyclins D1, D3 and p27 in thymic epithelial tumors. 9 38
17670226 2004
33
Hematopoietic progenitor cells as possible origins of epithelial thymoma in a human T lymphocyte virus type I pX gene transgenic rat model. 9 38
14688799 2004
34
Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. 9 38
14673901 2003
35
Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. 9 38
14652817 2003
36
Disease severity and outcome in thymoma myasthenia gravis: a long-term observation study. 9 38
14641516 2003
37
Increased thymocyte CD4+CD8+ cells and T-cell receptor beta gene rearrangements in thymoma. 9 38
14621007 2003
38
Role of antioxidant genes for the activity of artesunate against tumor cells. 9 38
12964009 2003
39
Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. 9 38
14592894 2003
40
Myasthenia gravis in individuals over 40. 9 38
14592910 2003
41
Expression status of E-cadherin and alpha-, beta-, and gamma-catenins in thymoma. 9 38
11899204 2002
42
Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? 9 38
11706095 2001
43
[Auto-antibodies against acetylcholine receptors in myasthenia gravis]. 9 38
11688208 2001
44
[The significance of Titin antibody in diagnosing myasthenia gravis with thymoma]. 9 38
11766610 2001
45
Titin, thymoma, and myasthenia gravis. 9 38
11405799 2001
46
Interleukin-1 beta induced synthesis of protein kinase C-delta and protein kinase C-epsilon in EL4 thymoma cells: possible involvement of phosphatidylinositol 3-kinase. 9 38
11549843 2001
47
DNA microarray reveals increased expression of thioredoxin peroxidase in thioredoxin-1 transfected cells and its functional consequences. 9 38
11764930 2001
48
Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis. 9 38
11182151 2001
49
IL-2 independent transformation of a unique human T cell line, TY8-3, and its subclones by HTLV-I and -II. 9 38
11149427 2001
50
The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. 9 38
11074791 2000

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 KIT NM_000222.2(KIT): c.1468G> A (p.Glu490Lys) single nucleotide variant Pathogenic rs1057519701 4:55592144-55592144 4:54725978-54725978
2 KIT NM_000222.2(KIT): c.1657T> A (p.Tyr553Asn) single nucleotide variant Pathogenic rs1057519704 4:55593591-55593591 4:54727425-54727425
3 KIT NM_000222.2(KIT): c.1730_1738del (p.Pro577_Asp579del) deletion Pathogenic rs1131692239 4:55593664-55593672 4:54727498-54727506
4 KIT NM_000222.2(KIT): c.2460T> A (p.Asp820Glu) single nucleotide variant Pathogenic rs1057519711 4:55599334-55599334 4:54733168-54733168
5 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 4:55593610-55593610 4:54727444-54727444
6 HRAS NM_005343.4(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 11:534285-534285 11:534285-534285
7 KIT NM_000222.2(KIT): c.1676_1678TTG[1] (p.Val560del) short repeat Pathogenic/Likely pathogenic rs121913685 4:55593612-55593614 4:54727447-54727449
8 KIT NM_000222.2(KIT): c.1727T> C (p.Leu576Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913513 4:55593661-55593661 4:54727495-54727495
9 KIT NM_000222.2(KIT): c.1669T> C (p.Trp557Arg) single nucleotide variant Likely pathogenic rs121913235 4:55593603-55593603 4:54727437-54727437
10 KIT NM_000222.2(KIT): c.2089C> T (p.His697Tyr) single nucleotide variant Uncertain significance rs763308199 4:55595599-55595599 4:54729433-54729433

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 RYR1 PTPRC KIT IL2 HRAS AKT3
2
Show member pathways
13.53 PTPRC PPL LCK KIT HRAS AKT3
3
Show member pathways
13.48 LCK KIT IL2 HRAS CD2 AKT3
4
Show member pathways
13.48 PTPRC PPL KIT IL2 HRAS EVPL
5
Show member pathways
13.36 TTN LCK IL2 HRAS CD2 AKT3
6
Show member pathways
13.34 PTPRC KIT IL2 HRAS CD2 AKT3
7
Show member pathways
13.29 PTPRC LCK IL2 HRAS AKT3 AKT2
8
Show member pathways
13.1 LCK KIT IL2 HRAS AKT3 AKT2
9
Show member pathways
13.07 KIT IL2 HRAS AKT3 AKT2 AKT1
10
Show member pathways
13 PTPRC LCK HRAS AKT3 AKT2 AKT1
11
Show member pathways
12.93 KIT HRAS AKT3 AKT2 AKT1
12 12.9 KIT IL2 HRAS AKT3 AKT2 AKT1
13
Show member pathways
12.85 IL2 HRAS AKT3 AKT2 AKT1
14 12.84 KIT HRAS AKT3 AKT2 AKT1
15
Show member pathways
12.84 KIT HRAS AKT3 AKT2 AKT1
16
Show member pathways
12.81 KIT HRAS AKT3 AKT2 AKT1
17
Show member pathways
12.76 LCK KIT HRAS AKT3 AKT2 AKT1
18
Show member pathways
12.72 NKX2-1 HRAS AKT3 AKT2 AKT1
19
Show member pathways
12.66 IL2 HRAS AKT3 AKT2 AKT1
20
Show member pathways
12.65 HRAS AKT3 AKT2 AKT1
21
Show member pathways
12.65 PTPRC HRAS AKT3 AKT2 AKT1
22 12.63 PTPRC LCK KIT IL2 CD2
23
Show member pathways
12.6 PTPRC LCK IL2 HRAS AKT3 AKT2
24
Show member pathways
12.58 PTPRC LCK HRAS AKT3 AKT2 AKT1
25
Show member pathways
12.56 HRAS AKT3 AKT2 AKT1
26
Show member pathways
12.55 HRAS AKT3 AKT2 AKT1
27
Show member pathways
12.5 HRAS AKT3 AKT2 AKT1
28
Show member pathways
12.5 HRAS AKT3 AKT2 AKT1
29
Show member pathways
12.49 IL2 HRAS AKT3 AKT2 AKT1
30
Show member pathways
12.47 HRAS AKT3 AKT2 AKT1
31
Show member pathways
12.46 HRAS AKT3 AKT2 AKT1
32
Show member pathways
12.45 KIT HRAS AKT3 AKT2 AKT1
33
Show member pathways
12.41 HRAS AKT3 AKT2 AKT1
34
Show member pathways
12.41 RYR1 HRAS AKT3 AKT2 AKT1
35
Show member pathways
12.41 PTPRC LCK IL2 HRAS AKT3 AKT2
36
Show member pathways
12.4 HRAS AKT3 AKT2 AKT1
37
Show member pathways
12.39 HRAS AKT3 AKT2 AKT1
38
Show member pathways
12.38 HRAS AKT3 AKT2 AKT1
39
Show member pathways
12.38 PTPRC LCK IL2 AKT3 AKT2 AKT1
40
Show member pathways
12.38 PTPRC LCK HRAS AKT3 AKT2 AKT1
41
Show member pathways
12.37 HRAS AKT3 AKT2 AKT1
42 12.37 HRAS AKT3 AKT2 AKT1
43 12.35 LCK IL2 HRAS AKT3 AKT2 AKT1
44
Show member pathways
12.31 PTPRC LCK IL2 HRAS AKT3 AKT2
45
Show member pathways
12.3 HRAS AKT3 AKT2 AKT1
46
Show member pathways
12.29 LCK AKT3 AKT2 AKT1
47
Show member pathways
12.28 PTPRC LCK HRAS AKT3 AKT2 AKT1
48
Show member pathways
12.27 HRAS AKT3 AKT2 AKT1
49
Show member pathways
12.27 HRAS AKT3 AKT2 AKT1
50 12.25 HRAS AKT3 AKT2 AKT1

GO Terms for Thymoma

Cellular components related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 THY1 PTPRC KIT CD5 CD2

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 KIT IL2 HRAS AKT2 AKT1
2 positive regulation of gene expression GO:0010628 9.88 TTN NKX2-1 KIT HRAS AKT1
3 phosphorylation GO:0016310 9.88 TTN LCK KIT AKT3 AKT2 AKT1
4 protein phosphorylation GO:0006468 9.8 TTN LCK KIT AKT3 AKT2 AKT1
5 regulation of cell migration GO:0030334 9.75 THY1 AKT2 AKT1
6 positive regulation of protein phosphorylation GO:0001934 9.73 IL2 HRAS AKT2 AKT1
7 negative regulation of protein kinase activity GO:0006469 9.7 THY1 PTPRC AKT1
8 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.6 THY1 LCK
9 negative regulation of protein tyrosine kinase activity GO:0061099 9.58 THY1 PTPRC
10 positive regulation of phospholipase C activity GO:0010863 9.57 KIT HRAS
11 mammary gland epithelial cell differentiation GO:0060644 9.56 AKT2 AKT1
12 positive regulation of mitochondrial membrane potential GO:0010918 9.55 AKT2 AKT1
13 negative thymic T cell selection GO:0045060 9.54 PTPRC AIRE
14 T cell costimulation GO:0031295 9.54 LCK CD5 AKT1
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.51 PTPRC IL2
16 positive regulation of glucose metabolic process GO:0010907 9.49 AKT2 AKT1
17 peripheral nervous system myelin maintenance GO:0032287 9.46 AKT2 AKT1
18 release of sequestered calcium ion into cytosol GO:0051209 9.33 RYR1 PTPRC LCK
19 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT2 AKT1
20 T cell receptor signaling pathway GO:0050852 9.26 THY1 PTPRC LCK HRAS
21 T cell differentiation GO:0030217 8.92 PTPRC LCK KIT IL2

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.73 TTN LCK KIT AKT3 AKT2 AKT1
2 protein kinase binding GO:0019901 9.72 TTN THY1 PTPRC LCK AKT1
3 protein binding GO:0005515 9.58 TTN THY1 RYR1 PTPRC PPL NKX2-1
4 enzyme binding GO:0019899 9.55 TTN THY1 RYR1 NKX2-1 AKT1
5 protease binding GO:0002020 9.54 TTN RYR1 KIT
6 protein kinase activity GO:0004672 9.43 TTN LCK KIT AKT3 AKT2 AKT1

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....